ASUNCIÓN, PARAGUAY – A company that began its journey 50 years ago in Paraguay as Fapasa has now undergone an innovative transformation, embracing a new name, Adium, that encompasses the entire region. Starting from its founding factory and expanding across Latin America, the company is ushering in a new era that honors its past, strengthens its present, and plans a future dedicated to innovation, well-being, and improving the quality of life for Latin Americans.
50 Years of History, a New Identity: The Birth of Adium
Adium's history began with the establishment of Fapasa in Paraguay in 1975. Since then, the company has achieved continuous innovation and sustained growth, culminating today in a unified regional identity. After a 50-year journey, the Adium Group has positioned itself as one of the leading companies in the Latin American pharmaceutical industry, operating in 18 countries and employing over 7,000 people. This reaffirms its half-century commitment to providing innovative treatments that improve the quality of life for patients across Latin America.
Paraguayan Hub, Leap Towards Latin America: Project Centauri
Central to this transformation is a significant investment in Paraguay. Specifically, 'Proyecto Centauri' is a strategic initiative by Adium, aiming to dramatically expand production capacity by introducing state-of-the-art technology and supplying medicines to the entire region from its founding factory. Through this project, Adium solidifies its production growth, accelerates its digital transformation, and reasserts its commitment to continuous innovation. Adium's operations in Paraguay generate over 800 direct jobs, significantly impacting the nation's economic and social development.
Paraguay plays a crucial role as a strategic production and export hub for the Adium Group. The Paraguayan factory produces over 45 million units of medicine annually, supplying 11 international markets and accounting for over 50% of Paraguay's total pharmaceutical exports. This production capacity and export performance are key to Adium maintaining its leading position in the Latin American pharmaceutical market.
Extensive Therapeutic Areas and Global Collaborations
Adium is developing a portfolio across various major therapeutic areas, including cardiology, psychiatry, gastroenterology, gynecology, traumatology, and diabetes. Particularly in complex fields such as oncology, hematology, central nervous system disorders, and urology, it collaborates with leading innovative healthcare companies like Amgen, Astellas, BMS, and Debiopharm to introduce cutting-edge treatments. These partnerships reflect Adium's ongoing efforts to provide solutions that transform patients' lives and enhance innovation across Latin America.
Social Responsibility Through Education and Awareness
Adium also enhances access to medical education through platforms like Adium Pro and promotes patient support programs and awareness campaigns for various diseases and prevention. In Paraguay, these initiatives lead to engagements with medical professionals, customized educational materials, and community awareness activities, further solidifying Adium's commitment to innovation, health, and quality of life.
Commitment to Sustainability
Sustainability is also a core part of Adium's DNA. In Paraguay, Adium collaborates with the 'A Todo Pulmón' organization on concrete activities such as reforestation, environmental education, and community awareness. This demonstrates Adium's strong commitment to environmental protection and collective well-being alongside industrial development.
Adium's transformation reaffirms the ultimate purpose that has guided every step of the group over the past 50 years: the promise to deliver innovative treatments to improve the quality of life for people throughout Latin America.
[Copyright (c) Global Economic Times. All Rights Reserved.]
